16. Tursi A, Brandimarte G, Giorgetti GM. Prevalence of antitissue transglutaminase antibodiesin different degrees of intestinal damage in celiac disease. J Clin Gastroenterol.2003;36:219–221.68
Association of <strong>Celiac</strong> <strong>Disease</strong> and Gastrointestinal (GI)Lymphomas and Other GI Cancers Carlo Catassi, M.D., M.P.H.The association between celiac disease (CD) and cancer is long established. The mostfrequent malignant complication of CD is a high-grade T-cell non-Hodgkin lymphoma (NHL) ofthe upper small intestine, usually defined as enteropathy-associated T-cell lymphoma (EATL). Ithas been suggested that patients with CD carry an increased risk of developing malignanciesother than NHL, especially small-intestinal adenocarcinoma and oesophageal and pharyngealsquamous carcinomas. (1)Recent epidemiological studies have shown that CD is one of the most common life-longdisorders in Western countries, affecting around 1 percent of the general population. Currently,most cases remain undiagnosed and are exposed to the risk of long-term complications. (2) For thisreason, the CD–cancer connection has gained a renewed interest, as this treatable disorder couldtheoretically represent a major risk factor for NHL and other malignancies.CD-Associated GI CancersEATL is an intestinal T-cell lymphoma that peaks in the sixth decade of life. With anannual incidence rate of 0.5–1 per million people in Western countries, this is a rare form ofcancer covering around 35 percent of all small bowel lymphomas. (3) By definition, this NHLsubtype arises in patients with either previously or concomitantly diagnosed CD. Occasionally,CD is recognized after the diagnosis of lymphoma has been made. The EATL immunophenotypeis consistent with a derivation from a clonal proliferation of intraepithelial lymphocytes (IEL). Insome cases EATL represents the end-stage evolution of refractory celiac sprue (RCS). RCS isdefined as symptomatic villous atrophy not responding to gluten-free diet (GFD) in a subjectinitially showing diagnostic features of CD. In approximately 80 percent of RCS cases, anabnormal clonal IEL population can be shown, frequently diffused along the intestinal tract,characterized by a low ratio of CD + 8/CD + 3and TCR gene rearrangement. This entity should beclassified as “cryptic EATL” as it is associated with a high risk of ulcerative jejunitis andlymphomatous transformation. (4)EATL commonly develops in the jejunum but may also be found in the ileum and lymphnodes, and less frequently in the stomach and the colon. It is often multifocal with ulcerativelesions. Extranodal presentations are not uncommon in the liver/spleen, thyroid, skin, nasalsinus, etc. Most patients present with malaise, anorexia, weight loss, and diarrhea, oftenassociated with abdominal pain. Physical signs include fever, lymphadenopathy, skin rash,hepatomegaly, and a palpable abdominal mass. Approximately 50 percent of patients requirelaparotomy for complications of haemorrhage, perforation, or obstruction. The suspicion ofEATL prompts an extensive diagnostic workup that may include upper and lower intestinalendoscopy, CT scan with enteroclysis, or small bowel follow through; either push or wirelessvideo-capsule enteroscopy. The final diagnosis is made on either endoscopic biopsies or fullthickness laparoscopic small bowel biopsies. The immunoistochemical study shows a large- ormedium-size T-cell proliferation mainly expressing a CD 3+, CD 8-, CD 103+phenotype. In most69
- Page 1 and 2:
NIH Consensus Development Conferenc
- Page 3 and 4:
III. What Are the Manifestations an
- Page 5 and 6:
• What is the management of celia
- Page 7 and 8:
Monday, June 28, 2004 (continued)I.
- Page 9 and 10: Monday, June 28, 2004 (continued)II
- Page 11 and 12: Wednesday, June 30, 2004 (continued
- Page 13 and 14: Lisa H. RichardsonConsumer Represen
- Page 15 and 16: Ciaran P. Kelly, M.D.Director, Celi
- Page 17 and 18: Van S. Hubbard, M.D., Ph.D.Director
- Page 19 and 20: AbstractsThe following are abstract
- Page 21 and 22: susceptibility (e.g., DR17 homozygo
- Page 23 and 24: The Pathology of Celiac DiseaseDavi
- Page 25 and 26: In this regard, the transport pathw
- Page 27 and 28: for the IgG-based test, while speci
- Page 29 and 30: 15. de Lecea A, Ribes-Koninckx C, P
- Page 31 and 32: Clinical Algorithm in Celiac Diseas
- Page 33 and 34: Considera diagnosisof celiac diseas
- Page 35 and 36: There are populations at particular
- Page 37 and 38: Serological Testing for Celiac Dise
- Page 39 and 40: Estimates of the sensitivity of the
- Page 41 and 42: the risk and severity of CD may als
- Page 43 and 44: What Are the Prevalence and Inciden
- Page 45 and 46: ascribed to excess menstrual loss.
- Page 47 and 48: ReferencesFamily History of Celiac
- Page 49 and 50: Carroccio A, Iannitto E, Cavataio F
- Page 51 and 52: identified by surveys or through so
- Page 53 and 54: Clinical Presentation of Celiac Dis
- Page 55 and 56: een widely reported. The question r
- Page 57 and 58: The Many Faces of Celiac Disease: C
- Page 59: References1. Green PH, Jabri B. Coe
- Page 63 and 64: Does the Gluten-Free Diet Protect F
- Page 65 and 66: Skin Manifestations of Celiac Disea
- Page 67 and 68: allow a better understanding of the
- Page 69 and 70: 4. Henriksson KG, Hallert C, Walan
- Page 71 and 72: characterized, clinically-identifie
- Page 73 and 74: 10. Hoffenberg EJ, Emery LM, Barrig
- Page 75 and 76: ataxia, epilepsy with posterior cer
- Page 77 and 78: Consequences of Testing for Celiac
- Page 79 and 80: Osteoporosis/FracturesThere were 11
- Page 81 and 82: Dietary Guidelines for Celiac Disea
- Page 85 and 86: 21. Thompson T. Thiamin, riboflavin
- Page 88 and 89: In order to effectively counsel ind
- Page 90 and 91: 9. Hallert C, Granno C, Hulten S, M
- Page 92 and 93: adhered to the GFD after more than
- Page 94 and 95: Patient education, close supervisio
- Page 96: 26. Mustalahti K, Lohiniemi S, Laip
Change language